Author

Nathan A. Ellis

University of ArizonaORCID 0000-0003-4231-502XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1 Research Focus:variant calling· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. Philip McMahon· 1 shared Aditi Mandar Atmasidha· 1 shared Alan R. PrescottiD· 1 shared Alessandra Fistrovich· 1 shared Amy Dunne MilleriD· 1 shared Anthony J. ChalmersiD· 1 shared Antònia Obrador‐HeviaiD· 1 shared Carly R. CabeliD· 1 shared

Activity by Year

2021-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Philip McMahon

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 26, 2025

Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signalling

Vasudha Tandon, Alessandra Fistrovich, Joaquina Nogales…·Sourav Banerjee

This paper designs and evaluates Dyr726, a brain-penetrant multi-kinase inhibitor that targets PI3Kα, receptor tyrosine kinases, and WNT signaling, showing efficacy in preclinical cancer models.

DOI 10.1101/2025.03.26.645490

mouseexperimental assay

𝕏 PostBluesky

GenomicsbioRxivPreprintSep 28, 2021

Mutational signature profiling classifies subtypes of clinically different mismatch repair deficient tumors with a differential immunogenic response potential

Mar Giner-Calabuig, Seila De Leon, Julian Wang…·Rosa M. Xicola

This study classifies MMR-deficient tumors into subtypes based on mutational signatures and immunogenic potential, revealing clinical and molecular differences.

DOI 10.1101/2021.09.28.460630

humanwhole-exome sequencing

𝕏 PostBluesky